Behavioral
Medtrans
Medtrans was paid $20.47M by Medicaid between Jan 2018 and Jan 2024, across 90 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 15% of everything it billed.
33Billing provider infoMEDTRANS
LAS VEGAS, NV 89122
LAS VEGAS, NV 89122
33aNPI1871915892assigned 01/10/2014
33bProvider typeAddiction (Substance Use Disorder) Counselor
28Total paid$20.47M
24GClaims401,427
24DCodes billed90
24AFirst – last monthJan 2018 – Jan 2024
Compared with peers
Next to other Addiction (Substance Use Disorder) Counselor providers in Nevada
Rank by total paid#1 of 107
Median peer was paid$33K
This provider vs. median625×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MALINIS, FRANCES controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,508 | $537K | |
| 2019 | 87,961 | $5.39M | |
| 2020 | 130,531 | $6.06M | |
| 2021 | 125,462 | $7.13M | |
| 2022 | 22,952 | $1.28M | |
| 2023 | 2,969 | $72K | |
| 2024incomplete | 44 | $0.00 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 45,467 | 39,409 | $3.14M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 14% | 15,832 | 13,814 | $2.85M |
| T1016 | Case management, each 15 minutes | 13% | 94,043 | 31,782 | $2.64M |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 8.3% | 2,697 | 2,269 | $1.70M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 7.8% | 16,383 | 7,706 | $1.59M |
| S9480 | Intensive outpatient psychiatric services, per diem | 6.2% | 10,798 | 2,957 | $1.27M |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 4.2% | 22,945 | 20,215 | $853K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.4% | 5,747 | 4,205 | $704K |
| H2017 | Psychosocial rehabilitation, billed per 15 minutesPsychosocial rehabilitation services, per 15 minutes | 3.1% | 7,958 | 1,889 | $644K |
| 90792 | Psychiatric diagnostic evaluation with medical services | 2.9% | 7,757 | 6,765 | $596K |
| T2001 | Non-emergency transportation; patient attendant/escort | 2.8% | 54,735 | 15,278 | $573K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 18,343 | 12,449 | $538K |
78 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 2.6% | 12,104 | $528K |
| Q3014 | Telehealth originating site facility fee | 2.1% | 20,280 | $432K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 1.9% | 2,345 | $388K |
| H2014 | Skills training and development, per 15 minutes | 1.1% | 5,538 | $222K |
| H0031 | Mental health assessment, by non-physician | 1.1% | 1,590 | $219K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,064 | $180K |
| 99490 | Ccm add 20min | <1% | 6,798 | $162K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 4,841 | $139K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,147 | $111K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,433 | $97K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,857 | $93K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,012 | $87K |
| H0001 | Alcohol and/or drug assessment | <1% | 507 | $68K |
| H0010 | Alcohol and/or drug services; sub-acute detoxification (residential addiction program inpatient) | <1% | 391 | $62K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,081 | $57K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,231 | $55K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 893 | $52K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 375 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,815 | $39K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 413 | $36K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,315 | $32K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 427 | $31K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 330 | $28K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 359 | $24K |
| 90839 | <1% | 236 | $24K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 2,034 | $19K |
| 80306 | <1% | 1,467 | $17K | |
| 99386 | <1% | 226 | $17K | |
| 82075 | <1% | 2,202 | $16K | |
| 99385 | <1% | 241 | $13K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 648 | $12K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 297 | $11K |
| 86580 | <1% | 2,848 | $11K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 78 | $8K |
| 80305 | <1% | 1,351 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 460 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 443 | $7K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 133 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 31 | $2K |
| 99201 | <1% | 131 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 43 | $1K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 123 | $1K |
| 87102 | <1% | 288 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 16 | $1K |
| 90674 | <1% | 58 | $998.88 | |
| 90686 | <1% | 71 | $955.47 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 68 | $884.54 |
| 81025 | <1% | 213 | $751.68 | |
| H0034 | Medication training and support, per 15 minutes | <1% | 34 | $560.34 |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | <1% | 21 | $434.20 |
| H0049 | Alcohol and/or drug screening | <1% | 49 | $399.75 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 12 | $236.88 |
| 98967 | <1% | 181 | $45.14 | |
| 99422 | <1% | 191 | $36.69 | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 438 | $27.71 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 18 | $2.29 |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 57 | $0.01 |
| 3079F | 0% | 127 | $0.00 | |
| 3008F | 0% | 1,675 | $0.00 | |
| 3074F | 0% | 214 | $0.00 | |
| 3080F | 0% | 243 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 266 | $0.00 |
| 99407 | 0% | 95 | $0.00 | |
| T2022 | Case management, per month | 0% | 106 | $0.00 |
| 99000 | 0% | 102 | $0.00 | |
| 99406 | 0% | 71 | $0.00 | |
| 3075F | 0% | 15 | $0.00 | |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | 0% | 46 | $0.00 |
| 3015F | 0% | 215 | $0.00 | |
| 3725F | 0% | 1,841 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 918 | $0.00 |
| 99423 | 0% | 17 | $0.00 | |
| 3077F | 0% | 391 | $0.00 | |
| 3078F | 0% | 255 | $0.00 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 209 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 13 | $0.00 |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 0% | 16 | $0.00 |
| 99421 | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMALINIS, FRANCES (CREDENTIALING SPECIALIST)
| Provider | Location | Paid |
|---|---|---|
| New Hope Placement, LLC | Las Vegas, NV | $11.03M |
| New Hope Placement, LLC | Reno, NV | $6.34M |
| Medtrans Reno Casal PLLC | Reno, NV | $3.39M |
| Medtrans Reno Casal PLLC | Reno, NV | $2.24M |
| Transformations Care LLC | Las Vegas, NV | $2.17M |
| Medtrans Reno Casal PLLC | Reno, NV | $1.33M |
| Transformations Care | Reno, NV | $818K |
| Well Care Foundation INC | Reno, NV | $285K |
| Medtrans, LLC | Las Vegas, NV | $67K |
| Homebase Care Casal PLLC | Reno, NV | $27K |
| Medtrans Reno Casal PLLC | Reno, NV | $16K |
| Medtrans Reno Casal, PLLC | Reno, NV | $4K |
| Homebase Care Casal PLLC | Reno, NV | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.